Document:

Form of Amendment to Convertible Secured Promissory Note

 Exhibit 10.52 
 WAIVER AND AMENDMENT TO 
 CONVERTIBLE SECURED PROMISSORY NOTE 
 This Amendment to Convertible Secured Promissory Note (this “Amendment”) is entered into as of December 27, 2007 by and
between Catcher Holdings, Inc., a Delaware corporation (the “Company”), and the Purchasers (as defined below). This Amendment amends the Convertible Secured Promissory Notes (the “Notes”) issued
pursuant to the each of the Note and Restricted Stock Purchase Agreements, dated as of April 4, 2007 and June 20, 2007 by and among the Company and the persons and entities listed on Exhibit A thereto (each a
“Purchaser” and collectively, the “Purchasers”) (together the “Agreements”). Capitalized terms not otherwise defined herein shall have the meanings given in the Notes.

 RECITALS 
 WHEREAS, the Company and the Purchasers are parties to the Notes; 
 Whereas, Section 11 of the Notes
provide that all outstanding Notes may be amended with the written consent of the Company and Purchasers holding more than 50% of the aggregate Loan Amount outstanding under all Notes issued pursuant to the Agreements; and 
 WHEREAS, the Company and the holders of a majority of the aggregate Loan Amount outstanding under all Notes issued pursuant to the
Agreements desire to amend the Notes as set forth herein. 
 NOW, THEREFORE, in consideration of the
foregoing and of the mutual promises and covenants set forth herein, the parties agree as follows: 
  

	1.	AMENDMENT TO NOTE. Section 3 of each Note is hereby deleted and replaced by the following: 

 “Maturity. Unless sooner paid or converted in accordance with the terms hereof, the entire unpaid principal amount and all unpaid accrued
interest shall become fully due and payable on the earlier of (a) unless extended pursuant to Section 7(a)(i) below, the date that is two hundred forty (240) days after the date hereof, (b) the closing of a Next Financing
(as defined below), or (c) the acceleration of the maturity of this Note by the Holder upon the occurrence of an Event of Default (such earlier date, the “Maturity Date”).” 
  

	2.	AMENDMENT TO NOTE. Section 5(a) of each Note is hereby deleted and replaced by the following: 

 “(a) Conversion upon sale of Next Securities. In the event that the Company, at any time after the date of issuance of this Note and prior to
the payment in full of this Note, shall issue and sell equity securities (the “Next Securities”) to investors for aggregate proceeds of at least $5,000,000 to the Company and at a price not less than $0.50 per share (a
“Next Financing”), then the outstanding principal amount of this Note and all accrued but unpaid interest thereon shall automatically be converted at the closing of the Next 

 
Securities, into Common Stock at a conversion price equal to the conversion price defined in Section 6(a)(i). In connection with such conversion,
Holder agrees to execute and deliver to the Company any documents reasonably requested by the Company. As soon as is reasonably practicable after a conversion has been effected, the Company shall deliver to Holder a certificate or certificates
representing the number of shares of Common Stock issuable by reason of such conversion pursuant to this Section 5 in such name or names and such denomination or denominations as Holder has specified.” 
  

	3.	AMENDMENT TO NOTE. Section 5(b) of each Note is hereby deleted. 

  

	4.	INCREASE IN PRINCIPAL. The Company and the Purchasers acknowledge and agree that the extension of the Maturity Date pursuant to
this Amendment shall be deemed an extension granted pursuant to Section 7(a)(i) of the Note and therefore the principal amount of each Note shall increase by 7.692%. 

  

	5.	WAIVER. The Purchasers hereby waive any and all Events of Default under any of the Note, the Agreements, or the certain Security, Collateral Agency and
Collateral Sharing Agreement, dated as of August 21, 2007, by and among the Company and the Purchasers that may have occurred through the date hereof; provided, however, that that in no event shall such waiver apply to any future Events of
Default. 

  

	6.	NO OTHER AMENDMENT. Except as specifically amended by this Amendment, the Note shall continue in full force and
effect. In the event of any conflict between the terms of this Amendment and the Note, the terms of this Amendment shall govern and control. 

  

	7.	GOVERNING LAW. This Amendment shall be governed by and construed under the laws of the State of Virginia as applied to agreements among Virginia
residents entered into and to be performed entirely within Virginia. 

  

	8.	COUNTERPARTS. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 

  

	9.	SEVERABILITY. If one or more provisions of this Amendment are held to be unenforceable under applicable law, such provision shall be excluded
from this Amendment and the balance of the Amendment shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

  

	10.	ENTIRE AGREEMENT. This Amendment, together with the Notes, the Agreements and the agreements executed pursuant hereto and
thereto, constitutes the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. 

 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed
this Amendment as of the date first above written. 
  

	
	 COMPANY:
  
 CATCHER HOLDINGS, INC.
  
 By:                                      
                                        
                             
         Denis McCarthy
         Chief
Financial Officer
  
 PURCHASER:
  
 By:                                      
                                        
                             
  
 Its:                                      
                                        
                              

 [SIGNATURE PAGE TO AMENDMENT
TO CONVERTIBLE SECURED PROMISSORY NOTE]Separation Agreement and General Release

 Exhibit 10.1 
 SEPARATION AGREEMENT 
 AND GENERAL RELEASE 
 1. Scope of Agreement. This Separation Agreement and General Release (“Agreement”), covers all understandings between Giorgio D’Urso
(“D’Urso”) and IVAX Diagnostics, Inc. (“IVAX”), relating to D’Urso’s employment and separation from employment with IVAX. When used herein the term “IVAX” also includes any or all current or former
affiliated corporations, parent corporations, partnerships, divisions and subsidiaries, and the officers, directors, shareholders, employees, agents, attorneys, successors and assigns of IVAX. 
 2. Separation Date. D’Urso’s separation from employment in the form of a voluntary resignation will be effective as of the date he signs this
agreement. On the next regular pay day, D’Urso will be paid his earned salary through the Separation Date, less applicable payroll deductions, which covers all of IVAX’s payroll obligations to D’Urso. D’Urso acknowledges that no
other compensation, vacation pay, bonus, sick pay, personal day pay, or any other money is or will be owed to D’Urso by IVAX. D’Urso’s participation in the existing IVAX group health plan will cease December 31, 2007, after which
time D’Urso will have the right to continue his group health insurance under COBRA. D’Urso’s rights pursuant to COBRA will be sent to D’Urso under separate cover. 
 3. IVAX Consideration. For and in consideration of the promises made by D’Urso in Paragraph 4 of this Agreement, IVAX agrees as follows: 
  

	 	(a)	IVAX agrees to pay to D’Urso the total sum of $495,000.00, less applicable payroll deductions. In addition, should D’Urso choose to continue his group heath insurance
under COBRA, IVAX will pay the monthly insurance premiums on D’Urso’s behalf until the earlier of six months or until D’Urso becomes covered under another group health plan. D’Urso shall advise IVAX in writing immediately if he
becomes so covered. D’Urso acknowledges that these are amounts D’Urso is not otherwise entitled to receive absent this Agreement. D’Urso understands that no payment will be disbursed until both parties have executed the Agreement and
the seven-day revocation period set forth in paragraph 8 has expired. 

  

	 	(b)	IVAX agrees that all public filings and statements made by IVAX will reflect that D’Urso voluntarily resigned his positions at IVAX and that his separation from IVAX was
amicable. 

  

	 	(c)	IVAX agrees to respond to all reference checks concerning D’Urso with a neutral reference. A neutral reference is understood to include dates of employment, position(s) held,
and salary only. 

  

	 	(d)	 With the limited exception noted below, IVAX unconditionally releases, forever discharges, waives, and holds harmless D’Urso from each and every claim, cause
of action, right, liability, or demand of any kind and nature, in law or equity, whether or not presently known to exist, including, without limitation, those claims arising from, or relating to, D’Urso’s employment or separation from
employment with IVAX. This provision does not, however, encompass claims 

	 	 
asserting violations by D’Urso of federal securities laws, rules, or regulations, including, without limitation, the Sarbanes-Oxley Act. Other than the
limited claims excluded, this release is a full and final bar to any claims IVAX may have against D’Urso. 

 4. D’Urso
Consideration. For and in consideration of the promises made by IVAX in Paragraph 3 of this Agreement, D’Urso agrees as follows: 
  

	 	(a)	D’Urso agrees to voluntarily resign as director, officer, employee, or from any other positions held with IVAX as of the effective date of this Agreement.

  

	 	(b)	D’Urso unconditionally releases, forever discharges, waives, and holds harmless IVAX from each and every claim, cause of action, right, liability, or demand of any kind and
nature, in law or equity, whether or not presently known to exist, including, without limitation, those claims arising from, or relating to, D’Urso’s employment or separation from employment with IVAX. This general release is a full and
final bar to any claims D’Urso may have against IVAX, including, without limitation, any claims: 

  

	 	(i)	arising from D’Urso’s employment, pay, bonuses, vacation, or any other employee benefits, and other terms and conditions of employment or employment practices of IVAX;

  

	 	(ii)	relating to the separation of D’Urso’s employment with IVAX or the surrounding circumstances thereof; 

  

	 	(iii)	relating to any claims for punitive, compensatory, and/or retaliatory discharge damages; back and/or front pay claims and fringe benefits; or payment of any attorneys’ fees for
D’Urso; 

  

	 	(iv)	arising from any alleged violation of any and all federal, state or local laws, including, but not limited to, claims under the Civil Rights Act of 1866, 1871, 1964, and 1991,
Employee Retirement Income Security Act of 1974, the Rehabilitation Act of 1973, the Fair Labor Standards Act, the Equal Pay Act of 1963, the Occupational Safety and Health Act, the Immigration Reform Control Act of 1986, the Age Discrimination in
Employment of 1967, the Older Workers’ Benefit Protection Act, the Family and Medical Leave Act of 1993, the Worker Adjustment and Retraining Notification Act of 1989, the Florida Civil Rights Act, the Americans with Disabilities Act of 1990,
retaliation under the Workers’ Compensation statutes, (as any of these laws may have been amended) and/or any other labor, employment, or anti-discrimination laws; and/or 

  

	 	(v)	based on any contract, tort, (including, but not limited to, defamation, slander, libel, etc.), whistleblower, personal injury, or wrongful discharge theory.

  

	 	(c)	D’Urso also waives his right to recover in any action which may be brought on his behalf by any person or entity, including, but not limited to, any governmental department or
agency such as the Equal Employment Opportunity Commission, the Florida Commission on Human Relations or the Department of Labor. This Agreement does not prohibit 

	 	 
the filing of a charge with a government agency, but this Agreement does release any claim which D’Urso may have for monetary relief, reinstatement, or
for any other remedy for D’Urso, arising out of any proceeding before any government agency or court. If any agency or court should take jurisdiction over any matter in which D’Urso has a personal interest, whether initiated by D’Urso
or otherwise, D’Urso will promptly inform that agency or court that this Agreement constitutes a full and final settlement by D’Urso of all claims released under this Agreement. 

  

	 	(d)	D’Urso also agrees and promises that he has not engaged in any disparaging conduct directed at IVAX, and that he shall refrain from making any derogatory statements and/or
engaging in any disparaging behavior, and from directing anyone else to make any derogatory statements and/or engaging in any disparaging behavior, directed at or relating to IVAX and any of IVAX’s employees in the future.

  

	 	(e)	D’Urso also agrees that this Agreement does not, and shall not be construed to, constitute an admission by IVAX of any violation of any federal, state or local statute or
regulation, or any violation of any of D’Urso’s rights or of any duty owed by IVAX to D’Urso. 

  

	 	(f)	D’Urso agrees not to testify for, appear on behalf of, or otherwise assist in any way any individual, company, or agency in any claim against IVAX unless pursuant to a lawful
subpoena issued to D’Urso, except this will not apply for any federal, state, or local administrative agency investigation. If such a subpoena is issued, D’Urso will immediately notify IVAX and provide it with a copy of the subpoena.

  

	 	(g)	D’Urso understands and agrees that, effective on the date of D’Urso’s separation, D’Urso is no longer authorized to incur any expenses or obligations or
liabilities on behalf of IVAX. 

  

	 	(h)	D’Urso agrees to return all property belonging to IVAX. D’Urso agrees that he will not disclose any information obtained from D’Urso’s employment with IVAX that
is considered proprietary and confidential, and D’Urso agrees not to disclose such information to anyone at any time. 

  

	 	(i)	D’Urso further agrees that he will not directly or indirectly, divulge or disclose, for any purpose whatsoever, any information regarding IVAX’s business, including but
not limited to, trade secrets, systems, procedures, marketing techniques, manuals, cost information, price determination procedures, confidential reports and lists, customer lists, and other confidential information such as employment history and
earnings statements, obtained by or disclosed to him as a result of his employment with IVAX. 

  

	 	(j)	D’Urso agrees that, for a period of twelve (12) consecutive months following separation of employment with IVAX, D’Urso shall not be employed or retained by, own,
manage, consult, join, control, or act on behalf of any business in competition with IVAX Diagnostics, Inc., or its three subsidiaries: Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc. For purposes of this provision, competing
businesses are defined as those developing, manufacturing or marketing diagnostic reagents, instrumentation or software, wherever located. 

	 	(k)	D’Urso agrees that, for a period of twelve (12) consecutive months following separation of employment with IVAX, D’Urso shall not directly or indirectly employ,
attempt to employ, or solicit for employment any other employees of IVAX Diagnostics, Inc., or its three subsidiaries: Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc. that have been separated from employment for less than six
months, for any business providing the same or similar services as IVAX Diagnostics, Inc., Diamedix Corporation, Delta Biologicals S.r.l. or ImmunoVision, Inc. 

  

	 	(l)	D’Urso acknowledges that he has legal obligations pursuant to applicable federal and state securities laws, rules and regulations and agrees that he shall at all times comply
with all applicable federal and state securities laws, rules and regulations. 

 5. Attorneys’ Fees and Costs. In the event
that either party commences an action for damages, injunctive relief, or to enforce the provisions of the Agreement, the prevailing party in any such action shall be entitled to an award of its reasonable attorneys’ fees and all costs including
appellate fees and costs, incurred in connection therewith as determined by the court in any such action. 
 6. Modification. This Agreement
contains the entire agreement of the parties hereto and there are no agreements, understandings or representations made by IVAX or D’Urso, except as expressly stated herein, regarding this matter. This Agreement supersedes all prior agreements
and understandings between IVAX and D’Urso regarding this matter, including specifically the Employment Agreement dated October 1, 1998, and the Amendments to that Agreement dated February 24, 2004 and July 13, 2005. However,
this Agreement does not affect any non-competition, non-solicitation, and non-disclosure/confidentiality agreements between D’Urso and IVAX. No cancellation, modification, amendment, deletion, addition or other changes in this Agreement or any
provision hereof or any right herein provided shall be effective for any purpose unless specifically set forth in a subsequent written agreement signed by both D’Urso and an authorized representative of IVAX. 
 7. Time to Consider. D’Urso is hereby advised to consult with an attorney before signing this Agreement. D’Urso has forty-five (45) days
from the date he received this Agreement in which to consider and accept this Agreement by signing and returning this Agreement to David A. Buchsbaum, at Fisher & Phillips LLP, 450 East Las Olas Boulevard, Suite 800, Fort Lauderdale,
Florida 33301. D’Urso may, however, accept this Agreement at any time within those 45 days. 
 8. Effective Date. Both parties acknowledge
that this Agreement will not become effective or enforceable until seven (7) days from the date that D’Urso signs this Agreement. During this seven (7) day period, D’Urso may revoke this Agreement. If D’Urso or
D’Urso’s attorneys do not advise IVAX in writing within such seven (7) day period of his intent to revoke this Agreement, this Agreement will become effective and enforceable upon the expiration of the seven (7) days.
D’Urso’s notice of intent to revoke this Agreement must be submitted to David A. Buchsbaum, at Fisher & Phillips LLP, 450 East Las Olas Boulevard, Suite 800, Fort Lauderdale, Florida 33301, by 5:00 p.m. on the seventh day of the
signing of the Agreement. 

 9. Construction. D’Urso agrees that he has been given a reasonable and sufficient time period within
which to consider this Agreement, and fully understands its terms, content and effect. Having had the opportunity to obtain the advice of legal counsel to review and comment upon this Agreement, D’Urso agrees that this Agreement shall be
construed as if the parties jointly prepared it so that any uncertainty or ambiguity shall not be interpreted against any one party and in favor of the other. 
 10. Severability and Waiver. The parties agree that the covenants of this Agreement are severable and that if any single clause or clauses shall be found unenforceable, the entire Agreement shall not fail but shall be
construed and enforced without any severed clauses in accordance with the terms of this Agreement. The parties also agree that any failure by any party to enforce any right or privilege under this Agreement shall not be deemed to constitute waiver
of any rights and privileges contained herein. This Agreement is covered by the laws of the State of Florida. 
 11. Execution. This Agreement
may be executed in one or more counter-parts, each of which shall be deemed an original, but all of which taken together shall constitute one of the same instrument. 
 12. Adequacy of Consideration. The parties further acknowledge the adequacy of the additional consideration provided herein by each to the other, that this is a legally binding document, and that they
intend to be bound by and faithful to its terms. 
 13. Venue and Forum Selection: The parties agree that any legal action to enforce this
Agreement or to seek a judicial declaration regarding the validity of any provision of this Agreement shall be brought in Miami-Dade County, Florida. 
 -You Are Advised To Consult An Attorney Before Signing This Agreement- 
 I hereby accept and agree to abide by
this Agreement: 
  

							
	By:	 	 /s/ Giorgio D’Urso
	 	Date:	 	January 3, 2008
		 	Giorgio D’Urso
	
	IVAX Diagnostics, Inc.
				
	By:	 	 /s/ Kevin D. Clark
	 	Date:	 	January 3, 2008
		 	Kevin D. Clark,
		 	Chief Operating Officer

 To be Signed by D’Urso upon Receipt of Agreement: 
 I hereby acknowledge that I received a copy of this Separation Agreement and General Release on this 3rd day of January, 2008, and was informed that I have up to 45
days from this date to consider it before signing. 
  

	
	 /s/ Giorgio D’Urso

	Giorgio D’Urso

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]